Global Bacillus Anthracis Infections Market: Overview
Bacillus anthracis is a type of bacteria that causes an acute disease called anthrax. Bacillus anthracis can infect both animals and humans. Bacillus anthracis is able to form a bacterial spore and is able to survive for prolonged period of time, even for centuries, in any harsh and mild conditions. When the spores of Bacillus anthracis are inhaled, swallowed or adhered to a lesion, they get reactivated and start rapid multiplication in the body of host.
An important feature of Bacillus anthracis is it doesn’t spread from one person to another by direct contact. It gets spread by clothes, shoes and utensils used by infected person. The bacterium was discovered in 1876 by Robert Koch. The major symptoms of the disease are identified from cutaneous sites, gastrointestinal and pulmonary infections. Pulmonary infections such as, cold, flu, pneumonia and respiratory failure are considered as important indications for Bacillus anthracis infections. Whereas, major gastrointestinal symptoms include chronic GI pain, severe diarrhea and vomiting of blood. The anthrax caused to skin is also called as Hide Porter’s disease. This is very chronic and life-threatening disease in which the skin develops black center spotted boiled skin lesions. Although life-threatening, it does not cause any pain or sensation to patient, but gradually converts into necrotic ulcer. Diagnosis of Bacillus anthracis infection is done by gram test in laboratory, Ascoli test, PCR assays, chest CT scan and immunofluroscence microscopical diagnostic tests.
Obtain Report Details @
Global Bacillus Anthracis Infections Market: Major Segments
The market of Bacillus anthracis infection is segmented on the basis of treatments, such as, preventive treatment and disease treatment. Prevention treatment is divided into vaccines such as, Pasteur’s vaccine, Sterne’s vaccine, British anthrax vaccines, Russian Anthrax vaccines, and American anthrax vaccines (BioThrax) and prophylaxis care. Further, infection treatment include antibiotics (penicillin, ciprofloxacin, erythromycin, doxycycline and others), monoclonal antibodies, such as, Raxibacumab and others. Additionally, the market is segmented on the basis of geography, such as, North America, Europe, Asia-Pacific and Rest of the World (RoW). At present, North America and Europe are the most prominent markets, owing to growing prevalence of Bacillus anthracis infection and anthrax disease. However, Asia-Pacific and some countries in RoW region are expected to show very lucrative growth in the upcoming period, owing to rapidly growing prevalence and awareness about anthrax.
Global Bacillus Anthracis Infections Market: Drivers and Restraints
The market of Bacillus anthracis is expected to increase steadily during forecast period 2014 – 2020. This growth is anticipated to be driven by fatal nature of the disease, R&D practices to develop more efficient and specific drugs, rising awareness about the disease and use of anthrax spores for bioterrorism and bioweapons. Steadily growing prevalence and mortal nature of anthrax (although considered as orphan disease) are the most important drivers of this market. Since last few centuries, anthrax has killed millions of human and animal across the world. The mortality rate is around 80-85%. Further, due to rising threat of bio warfare and bioterrorism, this threat is expected to increase exponentially. Henceforth, the market is expected to grow at steady rate in the upcoming 5-10 years. Furthermore, due to R&D practices, a number of new formulations, such as, epimerox, CF-306, PMX-0231, PMX-225, EV-009 and many others are under pipeline studies and expected to enter in the market during forecast period 2014 – 2020. Entry of these formulations may propel the market growth to higher end. However, major hurdles include high cost of treatment and ignorance and false diagnosis of the symptoms, which may decrease the market growth to certain extent.
Global Bacillus Anthracis Infections Market: Companies Mentioned in the Report
Major players operating in the R&D practices and commercialization include ContraFect Corporation, Evolva SA, Aphios Corporation, Cellceutix Corporation and Microbiotix, Inc.
The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.
Fill the form for an exclusive sample of this report @
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We have an experienced team of Analysts, Researchers, and Consultants, who us e proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR Syndicated Research report covers a different sector – such as pharmaceuticals, chemical, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, our syndicated reports thrive to provide clients to serve their overall research requirement.
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
USA – Canada Toll Free: 866-552-3453
Browse market research blog: